Virtuoso Surgical Wins FDA Nod for Robotic Bladder System

Nashville, Tennessee, USA, November 10, 2026

FDA De Novo Authorization Introduces New Robotic Device Classification

The FDA’s De Novo pathway provides a regulatory route for certain novel medical devices for which there is no legally marketed predicate device of the same type, when general and special controls can provide reasonable assurance of safety and effectiveness. Through this authorization, the Virtuoso Endoscopy System becomes the first device in the new classification for electromechanical surgical systems used in endoluminal procedures. Its authorized use is specifically for urologic surgery in the bladder where a transurethral approach is appropriate. The system is intended for trained surgeons working in an operating-room environment. Its role is to facilitate the removal of bladder lesions in an intact specimen, allowing pathologists to examine the tissue and assess features important to cancer diagnosis and staging. In conventional transurethral resection of bladder tumors (TURBT), lesions are commonly removed in fragments. This can make it more difficult to evaluate the complete tumor structure and surgical margins. En bloc resection, by contrast, aims to remove a lesion in one piece or in larger intact sections, potentially preserving more of the tissue architecture needed for pathological assessment. The FDA authorization therefore provides a new surgical technology option for eligible adult patients requiring endoscopic removal of bladder lesions.

Miniature Robotic Arms Enable Two-Handed Endoscopic Surgery

The Virtuoso Endoscopy System uses two needle-sized robotic arms positioned at the tip of a rigid endoscope. The arms are made from superelastic concentric nitinol tubes and are controlled by the surgeon through a console. This design enables two-handed manipulation within the bladder through the urethra, without requiring an external robotic surgical approach or additional abdominal incisions. During the procedure, one robotic arm can lift and retract the tumor while the second arm performs dissection beneath the lesion. This coordinated movement is intended to help surgeons separate the tumor from surrounding tissue and retrieve it as an intact specimen. The technology addresses a technical challenge associated with conventional endoscopic instruments, which can make en bloc removal difficult, particularly for surgeons who have limited experience with the technique. The robotic platform was developed using concentric tube technology originating from research at Vanderbilt University, Johns Hopkins University and Vanderbilt University Medical Center. The company believes that miniaturized robotic instruments can expand the capabilities of endoscopic surgery by providing greater dexterity in confined anatomical spaces. However, the FDA authorization applies only to the specified bladder indication; potential applications in other specialties remain investigational.

VIABLE Study Reports Promising Early Clinical Findings

Clinical evidence supporting the system comes from the company-sponsored VIABLE study (NCT06940648), which is evaluating the safety and effectiveness of robotic-assisted en bloc bladder lesion resection. Among the first 20 patients treated at The Chinese University of Hong Kong, detrusor muscle was present in 94% of resected lesions, exceeding the study’s predefined performance goal of 60%. Detrusor muscle is the muscular layer of the bladder wall and is important for determining how deeply a tumor has invaded. The company also reported that surgical margins could be evaluated in 93% of malignant lesions, while no intraoperative adverse events were reported among these first 20 patients. Earlier first-in-human findings from six patients involving 12 lesions showed that all lesions were removed using an en bloc or modified en bloc technique. Detrusor muscle was present in all 12 specimens, and evaluable margins were reported in 91% of urothelial tumors. These findings are encouraging but remain preliminary. The first 20-patient results come from a limited patient group at a single clinical site and may not predict outcomes in larger populations or routine commercial use. Virtuoso Surgical’s FDA De Novo authorization represents a notable step forward for robotic-assisted endoscopic surgery. As the company prepares for its planned 2027 U.S. launch, broader clinical experience will help establish how the system performs in clinical practice and how it may contribute to bladder cancer diagnosis and surgical management.

Source: Virtuoso Surgical press release